title: Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus.
abstract: BACKGROUND
  The sodium-dependent glucose co-transporter-2 (SGLT2) is expressed in absorptive epithelia of the renal tubules. Remogliflozin etabonate (RE) is the prodrug of remogliflozin, the active entity that inhibits SGLT2. An inhibitor of this pathway would enhance urinary glucose excretion (UGE), and potentially improve plasma glucose concentrations in diabetic patients. RE is intended for use for the treatment of type 2 diabetes mellitus (T2DM) as monotherapy and in combination with existing therapies. Metformin, a dimethylbiguanide, is an effective oral antihyperglycemic agent widely used for the treatment of T2DM.
  
  
  METHODS
  This was a randomized, open-label, repeat-dose, two-sequence, cross-over study in 13 subjects with T2DM. Subjects were randomized to one of two treatment sequences in which they received either metformin alone, RE alone, or both over three, 3-day treatment periods separated by two non-treatment intervals of variable duration. On the evening before each treatment period, subjects were admitted and confined to the clinical site for the duration of the 3-day treatment period. Pharmacokinetic, pharmacodynamic (urine glucose and fasting plasma glucose), and safety (adverse events, vital signs, ECG, clinical laboratory parameters including lactic acid) assessments were performed at check-in and throughout the treatment periods. Pharmacokinetic sampling occurred on Day 3 of each treatment period.
  
  
  RESULTS
  This study demonstrated the lack of effect of RE on steady state metformin pharmacokinetics. Metformin did not affect the AUC of RE, remogliflozin, or its active metabolite, GSK279782, although Cmax values were slightly lower for remogliflozin and its metabolite after co-administration with metformin compared with administration of RE alone. Metformin did not alter the pharmacodynamic effects (UGE) of RE. Concomitant administration of metformin and RE was well tolerated with minimal hypoglycemia, no serious adverse events, and no increase in lactic acid.
  
  
  CONCLUSIONS
  Coadministration of metformin and RE was well tolerated in this study. The results support continued development of RE as a treatment for T2DM.
  
  
  BACKGROUND
  ClinicalTrials.gov, NCT00376038.
authors: GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, NC 27709, USA.
authors: Elizabeth K
authors: EK
authors: Hussey
authors: Anita
authors: A
authors: Kapur
authors: Robin
authors: R
authors: O'Connor-Semmes
authors: Wenli
authors: W
authors: Tao
authors: Bryan
authors: B
authors: Rafferty
authors: Joseph W
authors: JW
authors: Polli
authors: Charles D
authors: CD
authors: James
authors: Robert L
authors: RL
authors: Dobbins
mesh_terms: D000328:Adult; D001786:Blood Glucose / Q000032:analysis; D018592:Cross-Over Studies; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy / Q000652:urine; D005260:Female; D005960:Glucosides / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics; D006029:Glycosuria; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics; D008297:Male; D008687:Metformin / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics; D008875:Middle Aged; D011355:Prodrugs / Q000008:administration & dosage* / Q000493:pharmacokinetics; D011720:Pyrazoles / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics; D051297:Sodium-Glucose Transporter 2; D000077203:Sodium-Glucose Transporter 2 Inhibitors
chemical_list: D001786:Blood Glucose; D005960:Glucosides; D007004:Hypoglycemic Agents; D011355:Prodrugs; D011720:Pyrazoles; C089180:SLC5A2 protein, human; D051297:Sodium-Glucose Transporter 2; D000077203:Sodium-Glucose Transporter 2 Inhibitors; D008687:Metformin; C532127:remogliflozin etabonate
references: Diabetes Metab Res Rev. 2005 Jan-Feb;21(1):31-8
references: 15624123
references: J Pharmacol Exp Ther. 2007 Jan;320(1):323-30
references: 17050778
references: Clin Pharmacokinet. 2011 Feb;50(2):81-98
references: 21241070
references: Lancet. 1998 Sep 12;352(9131):837-53
references: 9742976
references: Clin Pharmacol Ther. 2009 May;85(5):520-6
references: 19129748
references: Diabetes Care. 2008 Nov;31(11):2086-91
references: 18782901
references: Int J Clin Pract. 2008 Aug;62(8):1279-84
references: 18705823
references: Int J Clin Pract. 2005 Nov;59(11):1345-55
references: 16236091
references: Methods Find Exp Clin Pharmacol. 1995 Sep;17(7):483-7
references: 8577211
references: Br J Clin Pharmacol. 2001 Aug;52(2):137-44
references: 11488769
references: J Clin Pharmacol. 2010 Jun;50(6):636-46
references: 20200268
references: Diabetes Obes Metab. 2009 Feb;11(2):79-88
references: 19125776
references: J Clin Invest. 1994 Jan;93(1):397-404
references: 8282810
references: Drug Saf. 2005;28(7):601-31
references: 15963007
references: Int J Clin Pharmacol Ther Toxicol. 1990 Feb;28(2):72-8
references: 2307548
references: J Pharmacol Exp Ther. 2008 Oct;327(1):268-76
references: 18583547
references: Drug Metab Dispos. 2012 Nov;40(11):2090-101
references: 22851617
references: Clin Pharmacokinet. 2005;44(7):721-9
references: 15966755
references: Lancet. 1998 Sep 12;352(9131):854-65
references: 9742977
references: J Clin Pharmacol. 2010 Jun;50(6):623-35
references: 20056803
references: Curr Med Chem. 2004 Oct;11(20):2717-24
references: 15544472
references: BMC Pharmacol Toxicol. 2013 May 13;14:26
references: 23668634
references: Diabetes. 1995 Aug;44(8):968-83
references: 7622004
references: Diabetes Obes Metab. 2012 Jan;14(1):15-22
references: 21733056
references: Clin Pharmacokinet. 1996 May;30(5):359-71
references: 8743335
references: J Intern Med. 2007 Jan;261(1):32-43
references: 17222166
references: J Pharmacokinet Biopharm. 1987 Dec;15(6):657-80
references: 3450848
references: Arch Intern Med. 2003 Nov 24;163(21):2594-602
references: 14638559
references: Diabetologia. 2006 Aug;49(8):1711-21
references: 16802130
references: Diabetes Res Clin Pract. 1995 May;28(2):103-17
references: 7587918
references: Clin Pharmacol Ther. 2009 May;85(5):513-9
references: 19129749
references: Curr Opin Investig Drugs. 2007 Apr;8(4):285-92
references: 17458177
references: Br J Clin Pharmacol. 2009 Jan;67(1):130-1
references: 18823300
references: BMJ. 2000 Aug 12;321(7258):405-12
references: 10938048